Search
for
Sort by
Research 31–60 of 1000+
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
- Turpentine Ointment for the Treatment of Folliculitis: An Open, Prospective, Randomized, Placebo- and Comparator-Controlled Multicenter Trial
- Relapsing nail fibrokeratoma: A case report on a teenager
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Supplementary Material for: Turpentine ointment for the treatment of folliculitis – an open, prospective, randomized, placebo- and comparator-controlled multicenter trial
- Supplementary Material for: Turpentine ointment for the treatment of folliculitis – an open, prospective, randomized, placebo- and comparator-controlled multicenter trial
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
- Polynucleotides HPT for Asian Skin Regeneration and Rejuvenation
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Budesonide for maintenance of remission in Crohn's disease
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
- Type 2 Diabetes, Metabolic Syndrome and Lipid Metabolism
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
- Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
- Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
- Ritlecitinib in severe alopecia areata: a profile of its use
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Long‐Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real‐World Multicentric Case Series
- Trimodal mini-invasive therapy for stable-phase Peyronie's disease: a two-center real-life prospective pilot study
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata